William Fraser Symmans
William Fraser Symmans
Professor of Pathology, University of Texas MD Anderson Cancer Center
Verified email at
Cited by
Cited by
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
C Liedtke, C Mazouni, KR Hess, F André, A Tordai, JA Mejia, ...
Journal of clinical oncology 26 (8), 1275-1281, 2008
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, ...
Annals of oncology 26 (2), 259-271, 2015
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier, CM Perou, WF Symmans, N Ibrahim, M Cristofanilli, ...
Clinical cancer research 11 (16), 5678-5685, 2005
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy
WF Symmans, F Peintinger, C Hatzis, R Rajan, H Kuerer, V Valero, ...
J clin Oncol 25 (28), 4414-4422, 2007
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial
JC Boughey, VJ Suman, EA Mittendorf, GM Ahrendt, LG Wilke, B Taback, ...
Jama 310 (14), 1455-1461, 2013
The HER-2 receptor and breast cancer: ten years of targeted anti–HER-2 therapy and personalized medicine
JS Ross, EA Slodkowska, WF Symmans, L Pusztai, PM Ravdin, ...
The oncologist 14 (4), 320-368, 2009
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
K Stemke-Hale, AM Gonzalez-Angulo, A Lluch, RM Neve, WL Kuo, ...
Cancer research 68 (15), 6084-6091, 2008
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
JS Ross, JA Fletcher, GP Linette, J Stec, E Clark, M Ayers, WF Symmans, ...
The oncologist 8 (4), 307-325, 2003
Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update.
KH Allison, MEH Hammond, M Dowsett, SE McKernin, LA Carey, ...
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
KR Hess, K Anderson, WF Symmans, V Valero, N Ibrahim, JA Mejia, ...
Journal of clinical oncology 24 (26), 4236-4244, 2006
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models
Nature biotechnology 28 (8), 827-838, 2010
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes
H Masuda, KA Baggerly, Y Wang, Y Zhang, AM Gonzalez-Angulo, ...
Clinical cancer research 19 (19), 5533-5540, 2013
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised …
S Loibl, J O'Shaughnessy, M Untch, WM Sikov, HS Rugo, MD McKee, ...
The lancet oncology 19 (4), 497-509, 2018
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer
M Ayers, WF Symmans, J Stec, AI Damokosh, E Clark, K Hess, M Lecocke, ...
Journal of clinical oncology 22 (12), 2284-2293, 2004
An international Ki67 reproducibility study
MYC Polley, SCY Leung, LM McShane, D Gao, JC Hugh, ...
Journal of the National Cancer Institute 105 (24), 1897-1906, 2013
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer
L Gianni, M Zambetti, K Clark, J Baker, M Cronin, J Wu, G Mariani, ...
J Clin Oncol 23 (29), 7265-7277, 2005
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer
C Hatzis, L Pusztai, V Valero, DJ Booser, L Esserman, A Lluch, T Vidaurre, ...
Jama 305 (18), 1873-1881, 2011
Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype
WF Symmans, C Wei, R Gould, X Yu, Y Zhang, M Liu, A Walls, ...
Journal of Clinical Oncology 35 (10), 1049, 2017
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor …
AU Buzdar, V Valero, NK Ibrahim, D Francis, KR Broglio, RL Theriault, ...
Clinical Cancer Research 13 (1), 228-233, 2007
Adaptive randomization of veliparib–carboplatin treatment in breast cancer
HS Rugo, OI Olopade, A DeMichele, C Yau, LJ van’t Veer, MB Buxton, ...
New England Journal of Medicine 375 (1), 23-34, 2016
The system can't perform the operation now. Try again later.
Articles 1–20